SLS Stock News & Analysis | Latest Updates

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds

(NASDAQ:SLS) NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the immediate exercise of warrants, previously issued in January 2025, to purchase up to 19,685,040 shares of its common stock for gross cash proceeds of approximately $23.6 million.

September 11, 2025Capital

SELLAS Life Sciences Doses First Pediatric AML Patient In Ongoing Phase 2 Trial Of SLS009 r/r AML

SLS

May 15, 2025

SELLAS Life Sciences Gr Q1 EPS $(0.07) Beats $(0.10) Estimate

SLS

May 13, 2025

Sellas Life Sciences Presents Preclinical Efficacy Of SLS009 In TP53 Mutated AML Cells At AACR Conference

SLS

April 28, 2025

SELLAS Life Sciences Group Announced Cohort 3 Data From Ongoing Phase 2 Trial Of SLS009 In r/r AML

SLS

April 8, 2025

SELLAS Life Sciences Gr FY 2024 GAAP EPS $(0.50) Beats $(0.54) Estimate

SLS

March 20, 2025

SELLAS Announces Data From Phase 2a Trial Of SLS009 In Combination With Zanubrutinib In DLBCL; Combination Achieved A 67% Of Overall Response Rate; Median Overall Survival Not Reached Yet, 67% Of Patients Still Alive

SLS

February 20, 2025

SELLAS Life Sciences To Present Phase 2a Data On SLS009 For Relapsed/Refractory AML At ASH 2024, Showing 50% Response Rate And Median OS Of 5.5 Months At Selected Doses

SLS

November 5, 2024

SLS News